The information presented in this table is consistent with the information in the Health Information for International Travel 2010 (CDC's Yellow Book).

Country	Areas with Malaria	Estimated relative risk of Malaria for US Travelers2	Drug Resistance3	Malaria Species4	Recommended Chemoprophlaxis5	Helpful links for Select Countries
Gabon	All	High	Chloroquine	P. falciparum 95% P. malariae, P. ovale, P. vivax 5%	Atovaquone/ proguanil, doxycycline, or mefloquine
Gambia, The	All	High	Chloroquine	P. falciparum 85% P. malariae, P. ovale, P. vivax 15%	Atovaquone/ proguanil, doxycycline, or mefloquine
Georgia	Present June–Oct in the southeastern part of the country near the Azerbaijan border mainly in the Kakheti and Kveno Kartli regions. None in Tbilisi	Very Low	None	P. vivax 100%	Atovaquone/ proguanil, chloroquine, doxycycline, mefloquine, or primaquine7
Germany	None	None	Not Applicable	Not Applicable	Not Applicable
Ghana	All	High	Chloroquine	P. falciparum 85% P. ovale 5-10% P. vivax rare	Atovaquone/ proguanil, doxycycline, or mefloquine
Gibraltar (U.K.)	None	None	Not Applicable	Not Applicable	Not Applicable
Greece	Locally transmitted cases identified in agricultural areas of Evrotas in the Laconia (southeastern Peloponnese) region, and Marathon and Markopoulo in the East Attica region.	Very Low	None	P. vivax	Atovaquone/proguanil, chloroquine, doxycyline, mefloquine, and primaquine for agricultural areas of Evrotas, Laconia. Mosquito avoidance only for Marathon and Markopoulo.	Regions of Greece
Greenland (Denmark)	None	None	Not Applicable	Not Applicable	Not Applicable
Grenada	None	None	Not Applicable	Not Applicable	Not Applicable
Guadeloupe, including St. Barthelemy and Saint Martin (France)	None	None	Not Applicable	Not Applicable	Not Applicable
Guam (U.S.)	None	None	Not Applicable	Not Applicable	Not Applicable
Guatemala	Rural areas only at altitudes below 1,500 m (4,921 ft). None in Guatemala City, Antigua, or Lake Atitlán	Moderate	None	P. vivax 97% P. falciparum 3%	Atovaquone/ proguanil, chloroquine, doxycycline, mefloquine, or primaquine7	Altitude information for Guatemala
Guinea	All	High	Chloroquine	P. falciparum 85% P. ovale 5-10% P. vivax rare	Atovaquone/ proguanil, doxycycline, or mefloquine
Guinea-Bissau	All	No data	Chloroquine	P. falciparum 85% P. ovale 5-10% P. vivax rare	Atovaquone/ proguanil, doxycycline, or mefloquine
Guyana	Present in all rural areas below 900 m (2,953 ft).	Moderate	Chloroquine	P. falciparum 50% P. vivax 50%	Atovaquone/ proguanil, doxycycline, or mefloquine	Altitude information for Guyana

1. The information presented herein was accurate at the time of publication; however, factors that can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection, can markedly affect local malaria transmission patterns. Updated information may be found on the CDC Travelers' Health website at www.cdc.gov/travel.
2. This estimate of risk is based on numbers of cases of malaria reported in US travelers and the estimated volume of travel to these countries. In some instances the risk may be low because the actual intensity of transmission is low in that country. In other instances, significant malaria transmission may occur only in small focal areas of the country where US travelers seldom go. Thus even though the risk for the average traveler to that country may be low, the risk for the rare traveler going to the areas with higher transmission intensity will of course be higher. For some countries that are rarely visited by US travelers, there is insufficient information to make a risk estimate.
3. Refers to P. falciparum malaria unless otherwise noted.
4. Estimates of malaria species are based on best available data from multiple sources.
5. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
6. This risk estimate is based largely on cases occurring in US military personnel who travel for extended periods of time with unique itineraries that likely do not reflect the risk for the average US traveler.
7. Primaquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients must be screened for G6PD deficiency prior to starting primaquine.